Close Menu

Northrop Grumman

Using the publicly available ImmPort database, researchers standardized and analyzed immune-related data for more than 10,300 healthy individuals.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

Last month, during a forum organized by US News & World Report, Amy Caro, vice president of health IT programs at Northrop

Northrop Grumman received the award under the BioWatch Gen-3 System Performance Demonstration Contract, and said that the contract could be worth up to $37 million over three years.

Agilent Technologies, Columbia University, and others are collaborating on development of the system, which will be based on MassTag PCR.

The firms won grants to develop integrated diagnostic systems used to counter natural or man-made biological threats.

The companies will use Luminex's xMAP technology to develop an automated biothreat detection tool for a US biosecurity network.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.